Natco Pharma: The Exchange has received revised Disclosure

What happened

Natco Pharma (NATCOPHARM) filed a disclosure with the exchanges on 4 November 2026 at 03:31 PM titled "The Exchange has received revised Disclosure".

Company snapshot

Natco Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹13,999 crore.

The stock last traded at ₹781.6, against a 52-week range of ₹773.6–₹1,226.8 (36.3% below the high).

Before this filing the shares had moved −4.8% over the month and −14.8% over three months. Average daily turnover over the last 20 sessions was about ₹33.99 crore.

Promoters held 49.42% at the end of Q1 FY27. Foreign institutions owned 16.99% and domestic institutions 5.62%.

What history shows

BCEIE has no earlier pledge filing from this company on record since May 2026.

Across 35 similar disclosures by other Healthcare companies, shares moved −0.5% on average the next day and −0.1% over five days; 40% of them rose the next day.

Market-wide, 584 pledge filings with an impact score of 50 or more saw an average next-day move of +0.7%, with 51% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• 13 November 2026: Board meeting — Financial Results/Dividend.

In the news

Recent coverage elsewhere (links open the original publisher):

• NATCO Pharma Launches Generic Carboplatin Injection in the US — Machine Maker, 24 Oct 2026
• Khaitan & Co acts on NATCO Pharma ₹1,279 crore rights issue — Bar and Bench, 2 Nov 2026
• Natco Pharma opens trading window Oct 23-28 for rights issue credit — scanx.trade, 22 Oct 2026
• NATCO Pharma Launches Carboplatin Injection in the US to Address Supply Shortage — Machine Maker, 29 Oct 2026
• NATCO Pharma Rights Issue Closes 22 Oct 2026 — Kalkine India, 22 Oct 2026

Source

• Exchange filing (PDF)